title: Target-induced death by apoptosis in human lymphokine-activated natural killer cells.
abstract: Activated human natural killer (NK) cells undergo rapid apoptotic cell death after ligand binding to the Fc receptor (CD16). We examined whether human NK cells die after engagement in cytolytic functions. Peripheral blood NK cells, with and without prior activation in vitro with interleukin-2 (IL-2), were tested for the occurrence of cell death after incubation with K562, the prototype NK-sensitive target cell. A proportion (15.2%) of NK cells that were stimulated for 3 days with IL-2 and then incubated for 4 hours with K562 cells showed rapid cell death, but NK cells not stimulated with IL-2 did not. This cell death was found to involve nuclear condensation and fragmentation and DNA cleavage, all of which are characteristic of apoptosis. These data indicate that a proportion of activated human NK cells undergo apoptosis as they engage in target cell lysis. Target-induced NK cell death may represent an important mechanism for regulation of inflammatory processes involving NK cells.
authors.affiliation: Division of Haematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA.
authors.forename: K
authors.initials: K
authors.lastname: Taga
authors.forename: A
authors.initials: A
authors.lastname: Yamauchi
authors.forename: K
authors.initials: K
authors.lastname: Kabashima
authors.forename: E T
authors.initials: ET
authors.lastname: Bloom
authors.forename: J
authors.initials: J
authors.lastname: Muller
authors.forename: G
authors.initials: G
authors.lastname: Tosato
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D016227:Benzoquinones; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology* / Q000502:physiology / Q000648:ultrastructure; D047029:Lactams, Macrocyclic; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects*; D008854:Microscopy, Electron; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000502:physiology; D011809:Quinones / Q000494:pharmacology; D017452:Receptors, IgG / Q000502:physiology; D017828:Rifabutin / Q000031:analogs & derivatives; D014407:Tumor Cells, Cultured
chemical_list: D016227:Benzoquinones; D004791:Enzyme Inhibitors; D007376:Interleukin-2; D047029:Lactams, Macrocyclic; D011809:Quinones; D017452:Receptors, IgG; D017828:Rifabutin; C020754:herbimycin; D011505:Protein-Tyrosine Kinases